Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2665–2688 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Intraocular Pressure, Glaucoma
Interventions: iCare HOME2 vs iCare IC200; Device
Lead sponsor: Icare Finland Oy; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemia
Interventions: telephone counseling; Behavioral
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 40 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Infection, Heart Failure, COPD, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions: Home hospitalization, Traditional inpatient hospitalization; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pulmonary Hypertension
Interventions: Diagnostic imaging procedures.; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HIV Infections, HIV Metabolic Cardiovascular Syndrome, HIV Lipodystrophy, HIV Metabolic Syndromes, Hypertension
Interventions: Yoga lifestyle intervention, Standard of care; Behavioral · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sedentary Behavior, Behavior, Health, Cholesterolemia, Obesity, Stress, Hypertension, Fatigue, Glucose, High Blood, Mood
Interventions: Desk Only, Program Only; Device · Behavioral
Lead sponsor: Kansas State University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Manhattan, Kansas

Conditions: Aging, Medication Adherence, Hypertension
Interventions: Blood Pressure Technology System M, Blood Pressure Technology System E; Other
Lead sponsor: University of Arizona; Other
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Tucson, Arizona • Champaign, Illinois

Conditions: Portal Hypertension, Clinically Significant Portal Hypertension
Interventions: mpMRI, ARFI US; Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis, Hypertension
Interventions: naproxcinod 375 mg -750 mg -1125 mg bid, naproxen 250 mg - 500mg -750 mg bid; Drug
Lead sponsor: NicOx; Industry
Eligibility: 40 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 29
States / cities: Mobile, Alabama • Tempe, Arizona • Tucson, Arizona + 26 more

Conditions: Hypertension, Angina, Diabetes
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 39,481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 1
States / cities: No. Little Rock, Washington

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 19
States / cities: Phoenix, Arizona • Fresno, California • Los Angeles, California + 15 more

Conditions: Hypertension, Elevated Blood Pressure
Interventions: Vascanox® HP; Dietary Supplement
Lead sponsor: Calroy Health Sciences; Industry
Eligibility: 25 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pulmonary Arterial Hypertension
Interventions: Hyperpolarized 13C-pyruvate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Arterial Hypertension
Interventions: treprostinil diethanolamine; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Sickle Cell Disease
Interventions: Cardiac magnetic resonance imaging (CMR); Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypertension, Dyslipidemia
Interventions: Amlodipine/Atorvastatin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 106
States / cities: Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 73 more

Conditions: Preeclampsia
Interventions: Not listed
Lead sponsor: Carl Weiner, MD; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 431 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hypertension, Obesity
Interventions: Radio Story, Control -listened to a brochure; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions: QLS-111-FDC, Latanoprost (0.005%); Combination Product · Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Largo, Florida

Conditions: Hypertension, Elevated Blood Pressure
Interventions: Hot Yoga; Behavioral
Lead sponsor: Texas State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Marcos, Texas

Conditions: Elevated Intraocular Pressure (IOP)
Interventions: Travoprost Evolute® (Travoprost Punctal Plug Delivery System), 166 ug; Combination Product
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Glaucoma
Interventions: Optical Coherence Tomography; Diagnostic Test
Lead sponsor: Twin Cities Eye Consultants; Other
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Coon Rapids, Minnesota

Conditions: Glaucoma, Open-Angle
Interventions: Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution); Drug
Lead sponsor: Mankind Pharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Bakersfield, California • Mission Hills, California • Newport Beach, California + 5 more

Conditions: Ocular Hypertension, Glaucoma
Interventions: Massage, Experimental insert, Sham insert; Device · Procedure
Lead sponsor: Temple University; Other
Eligibility: 30 Years to 90 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

iCare HOME2 Clinical Trial

Improving Medication Adherence in Comorbid Conditions

Hospital-Level Care at Home for Acutely Ill Adults

Right Ventricular Hypertrophy and Pulmonary Hypertension: A Correlation Analysis

Yoga for the Management of HIV-Metabolic Syndromes

Stand Up Kansas: An Intervention to Reduce Sedentary Behavior in the Home Work Environment

Improving Hypertension Medication Adherence for Older Adults

Assessment of Portal Hypertension With Multiparametric MRI

A Study to Assess the Effects of Naproxcinod and Naproxen on Blood Pressure Measurements in Osteoarthritis Patients With Controlled High Blood Pressure

Improving Service Delivery Through Access Points

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Open Label Clinical Trial of Vascanox® HP on Nitric Oxide and Blood Pressure

Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease

Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population

A Study to Evaluate the Use of Placenta Protein 13 (PP13) in the First Trimester of Pregnancy as a Diagnostic Aiding Tool in the Assessment of the Risk for Developing Preeclampsia in Women With Low and Unknown Risk

Radio Stories About Children's Healthy Eating and Exercise

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

The Effects of Hot Yoga on Vascular Function

Safety and Intraocular Lowering Effect of Delivery of Travoprost Evolute® in Subjects With Elevated Intraocular Pressure

Comparison of Two OCT Device RNFL and GCIPL Measurements in Mild, Moderate, and Severe Glaucoma

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma

Foot Reflexology in Ocular Hypertensive and Glaucoma Patients